← Oncology Approval Tracker

FDA DECISION ·

Totect

dexrazoxane · Clinigen

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

To reduce the incidence and severity of doxorubicin-related cardiomyopathy in women with metastatic breast cancer who reached a cumulative 300 mg/m² of doxorubicin and would continue it for tumor control.

LAMPGEN ANALYSIS

Why it matters

Added a cardioprotective use to the Totect label for a defined cumulative-exposure group.

What research teams should watch

Reconcile cumulative anthracycline exposure and coordinate treatment timing and cardiac monitoring.

PRIMARY RECORDS

Sources